{"id":400385,"date":"2020-12-15T16:08:18","date_gmt":"2020-12-15T21:08:18","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=400385"},"modified":"2020-12-15T16:08:18","modified_gmt":"2020-12-15T21:08:18","slug":"penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\/","title":{"rendered":"Penumbra Announces Penumbra JET 7 Reperfusion Catheter with Xtra Flex Technology Voluntary Recall"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">ALAMEDA, Calif.<\/span>, <span class=\"xn-chron\">Dec. 15, 2020<\/span> \/PRNewswire\/ &#8212; Penumbra, Inc. (NYSE: PEN) today announced that it is voluntarily recalling all configurations of the Penumbra JET<span><sup>\u00ae<\/sup><\/span> 7 Reperfusion Catheter with Xtra Flex technology (JET 7 Xtra Flex). Penumbra is recalling JET 7 Xtra Flex because the catheter may become susceptible to distal tip damage during use. Distal tip damage in conjunction with pressurization or contrast injection may result in potential vessel damage, and subsequent patient injury or death.\u00a0Please refer to Penumbra&#8217;s website at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3013206-1&amp;h=3126809491&amp;u=http%3A%2F%2Fwww.penumbrainc.com%2Fnotifications&amp;a=www.penumbrainc.com%2Fnotifications\" rel=\"nofollow noopener noreferrer\">www.penumbrainc.com\/notifications<\/a>\u00a0to review the full recall advisory.\u00a0\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/282131\/penumbra_logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/282131\/penumbra_logo.jpg\" title=\"Penumbra, Inc. Logo (PRNewsFoto\/Penumbra, Inc.)\" alt=\"Penumbra, Inc. Logo (PRNewsFoto\/Penumbra, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <b>Conference Call and Webcast Information<br \/><\/b>Penumbra, Inc. will be hosting a conference call on <span class=\"xn-chron\">December 15<\/span>, 2020\u00a0at\u00a02:30 p.m. PST\u00a0to discuss this announcement. The conference call can be accessed live over the phone by dialing (833) 227-5837 for domestic callers or (647) 689-4064 for international callers (conference id: 7264926), or an audio webcast can be accessed on the &#8220;Events&#8221; section under the &#8220;Investors&#8221; tab of the Company&#8217;s website at: <u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3013206-1&amp;h=3994205946&amp;u=http%3A%2F%2Fwww.penumbrainc.com%2F&amp;a=www.penumbrainc.com\" rel=\"nofollow noopener noreferrer\">www.penumbrainc.com<\/a><\/u>. The webcast will be available on the Company&#8217;s website for at least two weeks following the completion of the call.<\/p>\n<p>\n        <b>About Penumbra <br \/><\/b>Penumbra, Inc., headquartered in <span class=\"xn-location\">Alameda, California<\/span>, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra sells its products to hospitals and healthcare providers primarily through its direct sales organization in <span class=\"xn-location\">the United States<\/span>, most of <span class=\"xn-location\">Europe<\/span>, <span class=\"xn-location\">Canada<\/span> and <span class=\"xn-location\">Australia<\/span>, and through distributors in select international markets. Penumbra, the Penumbra logo and Penumbra JET are trademarks of Penumbra, Inc. For more information, visit\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3013206-1&amp;h=3994205946&amp;u=http%3A%2F%2Fwww.penumbrainc.com%2F&amp;a=www.penumbrainc.com\" rel=\"nofollow noopener noreferrer\">www.penumbrainc.com<\/a>. <\/p>\n<p>\n        <b>Forward-Looking Statements<br \/><\/b>Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the impact of the COVID-19 pandemic on our business, results of operations and financial condition; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in\u00a0foreign currency exchange rates; and potential adverse regulatory actions. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended <span class=\"xn-chron\">December 31, 2019<\/span> filed with the SEC on <span class=\"xn-chron\">February 26, 2020<\/span>, our Quarterly Report on Form 10-Q for the quarter ended <span class=\"xn-chron\">March 31, 2020<\/span> filed with the SEC on <span class=\"xn-chron\">May 7, 2020<\/span>, our Quarterly Report on Form 10-Q for the quarter ended <span class=\"xn-chron\">June 30, 2020<\/span> filed with the SEC on <span class=\"xn-chron\">August 3, 2020<\/span>, and our Quarterly Report on Form 10-Q for the quarter ended <span class=\"xn-chron\">September 30, 2020<\/span> filed with the SEC on <span class=\"xn-chron\">November 2, 2020<\/span>. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business.\u00a0Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.<\/p>\n<p>\n        <b>Contact:<\/b>\n      <\/p>\n<p>\n        <b>Investor Relations<br \/><\/b>Penumbra, Inc.<br \/><a target=\"_blank\" href=\"mailto:investors@penumbrainc.com\" rel=\"nofollow noopener noreferrer\">investors@penumbrainc.com<\/a><br \/>510-995-2461<\/p>\n<p>\n        <b>Media Relations<br \/><\/b><br \/>\n        <span class=\"xn-person\">Betsy Merryman<\/span><br \/>\n        <br \/>Merryman Communications<br \/><a target=\"_blank\" href=\"mailto:betsy@merrymancommunications.com\" rel=\"nofollow noopener noreferrer\">betsy@merrymancommunications.com<\/a><br \/><a target=\"_blank\" href=\"mailto:media@penumbrainc.com\" rel=\"nofollow noopener noreferrer\">media@penumbrainc.com<\/a>\u00a0<br \/>310-560-8176<\/p>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=SF24214&amp;sd=2020-12-15\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall-301193471.html\">http:\/\/www.prnewswire.com\/news-releases\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall-301193471.html<\/a><\/p>\n<p>SOURCE  Penumbra, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=SF24214&amp;Transmission_Id=202012151605PR_NEWS_USPR_____SF24214&amp;DateId=20201215\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire ALAMEDA, Calif., Dec. 15, 2020 \/PRNewswire\/ &#8212; Penumbra, Inc. (NYSE: PEN) today announced that it is voluntarily recalling all configurations of the Penumbra JET\u00ae 7 Reperfusion Catheter with Xtra Flex technology (JET 7 Xtra Flex). Penumbra is recalling JET 7 Xtra Flex because the catheter may become susceptible to distal tip damage during use. Distal tip damage in conjunction with pressurization or contrast injection may result in potential vessel damage, and subsequent patient injury or death.\u00a0Please refer to Penumbra&#8217;s website at www.penumbrainc.com\/notifications\u00a0to review the full recall advisory.\u00a0\u00a0 Conference Call and Webcast InformationPenumbra, Inc. will be hosting a conference call on December 15, 2020\u00a0at\u00a02:30 p.m. PST\u00a0to discuss this announcement. The conference call can be accessed live over the phone &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Penumbra Announces Penumbra JET 7 Reperfusion Catheter with Xtra Flex Technology Voluntary Recall&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-400385","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Penumbra Announces Penumbra JET 7 Reperfusion Catheter with Xtra Flex Technology Voluntary Recall - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Penumbra Announces Penumbra JET 7 Reperfusion Catheter with Xtra Flex Technology Voluntary Recall - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire ALAMEDA, Calif., Dec. 15, 2020 \/PRNewswire\/ &#8212; Penumbra, Inc. (NYSE: PEN) today announced that it is voluntarily recalling all configurations of the Penumbra JET\u00ae 7 Reperfusion Catheter with Xtra Flex technology (JET 7 Xtra Flex). Penumbra is recalling JET 7 Xtra Flex because the catheter may become susceptible to distal tip damage during use. Distal tip damage in conjunction with pressurization or contrast injection may result in potential vessel damage, and subsequent patient injury or death.\u00a0Please refer to Penumbra&#8217;s website at www.penumbrainc.com\/notifications\u00a0to review the full recall advisory.\u00a0\u00a0 Conference Call and Webcast InformationPenumbra, Inc. will be hosting a conference call on December 15, 2020\u00a0at\u00a02:30 p.m. PST\u00a0to discuss this announcement. The conference call can be accessed live over the phone &hellip; Continue reading &quot;Penumbra Announces Penumbra JET 7 Reperfusion Catheter with Xtra Flex Technology Voluntary Recall&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-15T21:08:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/282131\/penumbra_logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Penumbra Announces Penumbra JET 7 Reperfusion Catheter with Xtra Flex Technology Voluntary Recall\",\"datePublished\":\"2020-12-15T21:08:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\\\/\"},\"wordCount\":670,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/282131\\\/penumbra_logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\\\/\",\"name\":\"Penumbra Announces Penumbra JET 7 Reperfusion Catheter with Xtra Flex Technology Voluntary Recall - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/282131\\\/penumbra_logo.jpg\",\"datePublished\":\"2020-12-15T21:08:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/282131\\\/penumbra_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/282131\\\/penumbra_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Penumbra Announces Penumbra JET 7 Reperfusion Catheter with Xtra Flex Technology Voluntary Recall\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Penumbra Announces Penumbra JET 7 Reperfusion Catheter with Xtra Flex Technology Voluntary Recall - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\/","og_locale":"en_US","og_type":"article","og_title":"Penumbra Announces Penumbra JET 7 Reperfusion Catheter with Xtra Flex Technology Voluntary Recall - Market Newsdesk","og_description":"PR Newswire ALAMEDA, Calif., Dec. 15, 2020 \/PRNewswire\/ &#8212; Penumbra, Inc. (NYSE: PEN) today announced that it is voluntarily recalling all configurations of the Penumbra JET\u00ae 7 Reperfusion Catheter with Xtra Flex technology (JET 7 Xtra Flex). Penumbra is recalling JET 7 Xtra Flex because the catheter may become susceptible to distal tip damage during use. Distal tip damage in conjunction with pressurization or contrast injection may result in potential vessel damage, and subsequent patient injury or death.\u00a0Please refer to Penumbra&#8217;s website at www.penumbrainc.com\/notifications\u00a0to review the full recall advisory.\u00a0\u00a0 Conference Call and Webcast InformationPenumbra, Inc. will be hosting a conference call on December 15, 2020\u00a0at\u00a02:30 p.m. PST\u00a0to discuss this announcement. The conference call can be accessed live over the phone &hellip; Continue reading \"Penumbra Announces Penumbra JET 7 Reperfusion Catheter with Xtra Flex Technology Voluntary Recall\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-15T21:08:18+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/282131\/penumbra_logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Penumbra Announces Penumbra JET 7 Reperfusion Catheter with Xtra Flex Technology Voluntary Recall","datePublished":"2020-12-15T21:08:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\/"},"wordCount":670,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/282131\/penumbra_logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\/","name":"Penumbra Announces Penumbra JET 7 Reperfusion Catheter with Xtra Flex Technology Voluntary Recall - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/282131\/penumbra_logo.jpg","datePublished":"2020-12-15T21:08:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/282131\/penumbra_logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/282131\/penumbra_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-recall\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Penumbra Announces Penumbra JET 7 Reperfusion Catheter with Xtra Flex Technology Voluntary Recall"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400385","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=400385"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400385\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=400385"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=400385"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=400385"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}